Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of SHR-3045 injection, a self-developed biological product aimed at treating rheumatoid arthritis [1] Group 1: Product Development - SHR-3045 injection is designed to inhibit immune cell function, reduce inflammation, and improve clinical symptoms in rheumatoid arthritis treatment [1] - The company has invested approximately 35.54 million yuan in the research and development of SHR-3045 injection to date [1] Group 2: Market Position - Currently, there are no similar drugs approved for market in both domestic and international markets [1]

Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司广东恒瑞医 药有限公司和上海恒瑞医药有限公司收到国家药品监督管理局（以下简称"国家 药监局"）核准签发关于 SHR-3045 注射液的《药 ...

Group 1 - A total of 173 stocks reached a 52-week high as of September 18, with notable performers including Brilliant Tomorrow (01351), Hong Kong Broadband (01310), and Meijie Holdings (01389) achieving high rates of 85.26%, 70.25%, and 70.21% respectively [1] - The top three stocks by closing price that reached their 52-week high are: Brilliant Tomorrow (0.600), Hong Kong Broadband (8.630), and Meijie Holdings (0.720) [1] - Other significant stocks that reached their 52-week high include Kaisa Capital (00936) at 50.00%, Yihua Tong (02402) at 42.86%, and Zhongyu Energy (03633) at 37.55% [1] Group 2 - The report includes a detailed list of stocks that reached their 52-week highs, with their respective closing prices and the percentage increase from their previous highs [1] - The data indicates a strong market performance, particularly in the technology and telecommunications sectors, as evidenced by the high rates of increase among the leading stocks [1] - The overall trend suggests a bullish sentiment in the market, with many stocks showing significant recovery or growth compared to their previous performance [1]

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with major indices dropping over 2% after reaching recent highs earlier in the day. The Hang Seng Index closed down 1.35%, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.46% and 0.99%, respectively [1][2]. Sector Performance - The technology sector, which had previously driven market gains, saw a broad pullback, with major financial stocks (banks, insurance, and brokerage firms) collectively dragging the market down. Real estate stocks faced substantial declines, reflecting ongoing market adjustments, with coal, home appliance, education, catering, gaming, and gold stocks also experiencing losses [2][3]. - Semiconductor stocks maintained strong performance amid news of anti-dumping investigations and rumors of a ban on Nvidia, with Huahong Semiconductor rising by 8.6% and leading firm SMIC reaching a historical high [2][10]. Notable Stock Movements - Major technology stocks such as Xpeng Motors, Haier Smart Home, and Bilibili saw declines exceeding 3%, while Tencent, Alibaba Health, and Midea Group also fell [4][5]. - Real estate stocks collectively dropped, with Country Garden falling over 10% and other firms like Jin Hui Holdings and Oceanwide Holdings declining by more than 7% [6]. - Chinese brokerage stocks also fell, with Hongye Futures down over 5% and other firms like Zhongzhou Securities and CITIC Securities following suit [7][8]. - Education stocks faced significant declines, with China Education Industry dropping over 9% and other firms like Zhongjiao Holdings and Huazhong Education also experiencing losses [9]. - The semiconductor and chip sectors saw gains, with ASMPT and Huahong Semiconductor both rising over 8% [10]. - The innovative drug sector performed well, with companies like Crystal Technology and Heng Rui Pharmaceutical seeing increases of over 5% [11]. Capital Flows - Southbound capital recorded a net inflow of HKD 6.288 billion, with net purchases of HKD 1.907 billion through the Shanghai-Hong Kong Stock Connect and HKD 4.382 billion through the Shenzhen-Hong Kong Stock Connect [13]. Future Outlook - Analysts predict a "super long bull market" for Hong Kong stocks, with expectations that the Hang Seng Index could reach around 28,000 points by November, and the Hang Seng Tech Index may target a range of 6,000 to 6,200 points [15].

Core Insights - The article highlights the current AH premium rates of various stocks, with Northeast Electric (00042) leading at 815.25% and Ningde Times (03750) at the bottom with -12.98% [1][2][3] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042) at 815.25% - Hongye Futures (03678) at 234.51% - Sinopec Oilfield Service (01033) at 222.78% [1][2] - The bottom three stocks with the lowest AH premium rates are: - Ningde Times (03750) at -12.98% - Heng Rui Pharmaceutical (01276) at -5.18% - Zijin Mining (02899) at 3.36% [1][3] Deviation Value Rankings - The stocks with the highest deviation values are: - Changfei Fiber Optic Cable (06869) at 29.36% - Northeast Electric (00042) at 28.81% - Zhaoyan New Drug (06127) at 26.44% [1][4] - The stocks with the lowest deviation values are: - Longyuan Power (00916) at -29.23% - Longpan Technology (02465) at -23.15% - Fosun Pharmaceutical (02196) at -22.01% [1][5]

Core Viewpoint - The Trump administration is drafting an executive order that will impose three major restrictions on commercial transactions involving Chinese innovative drug patents or rights, focusing on national security reviews by the Committee on Foreign Investment in the United States (CFIUS) [1][2]. Summary by Sections Executive Order Details - The draft includes three main provisions: 1. Inclusion of Chinese innovative drug BD transactions in the CFIUS mandatory review list, ending the previous "low-risk automatic exemption" practice [2]. 2. FDA will implement "racial sensitivity supplementary reviews" for drugs relying on Chinese clinical data, requiring at least 20% comparative data from non-Asian populations [2]. 3. Establishment of a "key drug domestic production fund" to provide production subsidies for 15 categories of drugs, including antibiotics and acetaminophen, while implementing a "domestic priority" principle in federal procurement [2]. Market Reaction - The market reacted swiftly to the policy risks, with the Hong Kong innovative drug index (HK1105) dropping 3.82% on September 11, 2025, and the A-share innovative drug sector (BK1106) declining 2.17%, with over 80% of stocks in the sector experiencing pullbacks [3]. - The following day, the indices showed signs of recovery, indicating investors' responses to policy uncertainties and rational corrections [3]. Globalization Trends - Despite the geopolitical risks, the trend of Chinese innovative drugs going global remains intact, with total license-out transactions to Europe and the U.S. reaching $9.43 billion as of September 2025 [3]. - Major transactions include a $950 million licensing deal between BeiGene and Royalty Pharma, and a $6 billion global licensing agreement between 3SBio and Pfizer, highlighting a shift towards milestone payments and regional licensing [3]. Industry Challenges - The domestic market faces challenges, with annual growth in medical insurance fund spending (approximately 12%) lagging behind the growth in innovative drug R&D investment (approximately 25%) [4]. - The average reduction in medical negotiations remains high at 54%, and commercial health insurance coverage for innovative drugs is below 15%, creating a supply-demand imbalance that necessitates going global [4]. Risk Resilience Assessment - Goldman Sachs has categorized Chinese innovative drug companies into three risk resilience tiers based on their sensitivity to policy changes and operational capabilities [4][5]. - Companies with mature global layouts exhibit the strongest resilience, while those heavily reliant on domestic markets show the weakest resilience [5][10]. Strategic Defense Framework - A three-dimensional defense system is proposed to address risks associated with the executive order, focusing on transaction review, data compliance, and supply chain security [13]. - Strategies include conducting national security risk pre-assessments for transactions over $50 million and establishing partnerships with U.S. law firms to navigate regulatory challenges [14][15]. Conclusion - The construction of a quantifiable "risk resilience index" is essential for Chinese innovative drugs in the global 2.0 era, emphasizing the need for companies to embed policy hedging clauses in transaction structures and consider racial diversity data in clinical stages [23].

恒瑞医药子公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗（SHR-A1811）的药品上市许可申请获受理，且已被纳入优先审评程序，本品适用于治疗既往接受过一种或 天风证券指出，恒瑞医药实现上半年归母净利润44.50亿元，同比增长29.67%；2025二季度归母净利润为25.76亿元，同比增长24.88%。2025上半年创新药进入快速放量阶段，国际化贡献利 责任编辑：卢昱君 恒瑞医药（01276）午前拉升逾7%，高见91港元，再创上市新高。截至发稿，股价上涨5.42%，现报89.50港元，成交额3.22亿港元。 ...

每经AI快讯，9月18日，港股恒瑞医药(01276.HK)午前拉升逾7%。截至发稿，涨7.18%，报91港元，成 交额2.98亿港元。 ...

Market Performance - The Hang Seng Index (HSI) rose by 469 points or 1.8%, closing at 26,908 points, reaching a four-year high of 26,936 points during the day[1] - The Hang Seng Tech Index increased by 256 points or 4.2%, closing at 6,334 points[1] - The total market turnover for the day was HKD 360.284 billion[1] Economic Indicators - The People's Bank of China conducted a reverse repurchase operation of CNY 418.5 billion at a steady rate of 1.4%, resulting in a net injection of CNY 114.5 billion for the day[1] - The RMB/USD midpoint was adjusted up by 14 points to 7.1013[1] U.S. Federal Reserve Actions - The Federal Reserve announced its first rate cut since December, lowering the benchmark overnight rate by 25 basis points to a range of 4% to 4.25%[2] - The Dow Jones Industrial Average rose by 260 points or 0.6% to close at 46,018 points following the rate cut[2] - The S&P 500 index fell by 6 points or 0.1%, while the Nasdaq dropped by 72 points or 0.3%[2] Trade Statistics - In July, Hong Kong's overall export volume increased by 12.6% and import volume rose by 14.3% compared to July of the previous year[3] - The overall export prices and import prices in July increased by 1.7% and 2% respectively compared to the same month last year[3]

消息面上，恒瑞医药子公司收到国家药监局下发的《受理通知书》，公司注射用瑞康曲妥珠单抗 （SHR-A1811）的药品上市许可申请获受理，且已被纳入优先审评程序，本品适用于治疗既往接受过一 种或一种以上抗HER2药物治疗的局部晚期或转移性HER2阳性成人乳腺癌患者。 天风证券指出，恒瑞医药实现上半年归母净利润44.50亿元，同比增长29.67%；2025二季度归母净利润 为25.76亿元，同比增长24.88%。2025上半年创新药进入快速放量阶段，国际化贡献利润持续增长。海 外授权收入持续增长，2025年至今授权首付款达7亿美元。随着管线持续丰富，未来三年创新药有望继 续保持高速增长。公司不断产出具有BIC潜力的产品。2025上半年，公司有15个自主研发的创新分子首 次进入临床阶段。考虑到公司创新药产品持续放量，维持"买入"评级。 智通财经APP获悉，恒瑞医药(01276)午前拉升逾7%，高见91港元，再创上市新高。截至发稿，涨 7.18%，报91港元，成交额2.98亿港元。 ...